These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

731 related articles for article (PubMed ID: 29486800)

  • 1. MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma.
    Sammon J; Fischer S; Menezes R; Hosseini-Nik H; Lewis S; Taouli B; Jhaveri K
    Cancer Imaging; 2018 Feb; 18(1):8. PubMed ID: 29486800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014.
    Horvat N; Nikolovski I; Long N; Gerst S; Zheng J; Pak LM; Simpson A; Zheng J; Capanu M; Jarnagin WR; Mannelli L; Do RKG
    Abdom Radiol (NY); 2018 Jan; 43(1):169-178. PubMed ID: 28765978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population.
    Wang Y; Yang Q; Li S; Luo R; Mao S; Shen J
    Clin Radiol; 2019 May; 74(5):407.e1-407.e10. PubMed ID: 30799097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of mass-forming intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma: based on the multivariate analysis of contrast-enhanced computed tomography findings.
    Zhao YJ; Chen WX; Wu DS; Zhang WY; Zheng LR
    Abdom Radiol (NY); 2016 May; 41(5):978-89. PubMed ID: 27193795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma.
    Tsunematsu S; Chuma M; Kamiyama T; Miyamoto N; Yabusaki S; Hatanaka K; Mitsuhashi T; Kamachi H; Yokoo H; Kakisaka T; Tsuruga Y; Orimo T; Wakayama K; Ito J; Sato F; Terashita K; Nakai M; Tsukuda Y; Sho T; Suda G; Morikawa K; Natsuizaka M; Nakanishi M; Ogawa K; Taketomi A; Matsuno Y; Sakamoto N
    Abdom Imaging; 2015 Aug; 40(6):1492-9. PubMed ID: 25579172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value.
    Sheng R; Yang C; Zhang Y; Wang H; Zheng B; Han J; Sun W; Zeng M
    Radiol Med; 2023 Sep; 128(9):1047-1060. PubMed ID: 37474663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial.
    Wildner D; Bernatik T; Greis C; Seitz K; Neurath MF; Strobel D
    Ultraschall Med; 2015 Apr; 36(2):132-9. PubMed ID: 25812115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinguishing intrahepatic mass-forming biliary carcinomas from hepatocellular carcinoma by computed tomography and magnetic resonance imaging using the Bayesian method: a bi-center study.
    Ichikawa S; Isoda H; Shimizu T; Tamada D; Taura K; Togashi K; Onishi H; Motosugi U
    Eur Radiol; 2020 Nov; 30(11):5992-6002. PubMed ID: 32500195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can machine learning radiomics provide pre-operative differentiation of combined hepatocellular cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma to inform optimal treatment planning?
    Liu X; Khalvati F; Namdar K; Fischer S; Lewis S; Taouli B; Haider MA; Jhaveri KS
    Eur Radiol; 2021 Jan; 31(1):244-255. PubMed ID: 32749585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI.
    Hwang J; Kim YK; Park MJ; Lee MH; Kim SH; Lee WJ; Rhim HC
    J Magn Reson Imaging; 2012 Oct; 36(4):881-9. PubMed ID: 22730271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral mass-forming cholangiocarcinoma in cirrhotic liver.
    Kim SJ; Lee JM; Han JK; Kim KH; Lee JY; Choi BI
    AJR Am J Roentgenol; 2007 Dec; 189(6):1428-34. PubMed ID: 18029881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MR comparative study of combined hepatocellular-cholangiocarcinoma in normal, fibrotic, and cirrhotic livers.
    Sheng RF; Xie YH; Ji Y; Chen CZ; Yang L; Jin KP; Zeng MS
    Abdom Radiol (NY); 2016 Nov; 41(11):2102-2114. PubMed ID: 27315077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging and clinical features of primary hepatic sarcomatous carcinoma.
    Shi D; Ma L; Zhao D; Chang J; Shao C; Qi S; Chen F; Li Y; Wang X; Zhang Y; Zhao J; Li H
    Cancer Imaging; 2018 Oct; 18(1):36. PubMed ID: 30314525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma.
    Granata V; Fusco R; Venanzio Setola S; Sandomenico F; Luisa Barretta M; Belli A; Palaia R; Tatangelo F; Grassi R; Izzo F; Petrillo A
    Radiol Oncol; 2020 May; 54(2):149-158. PubMed ID: 32463393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
    Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
    World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.
    Chi CT; Chau GY; Lee RC; Chen YY; Lei HJ; Hou MC; Chao Y; Huang YH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):125-133. PubMed ID: 30876788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation of Intrahepatic Cholangiocellular Carcinoma from Hepatocellular Carcinoma in the Cirrhotic Liver Using Contrast-enhanced MR Imaging.
    Wengert GJ; Baltzer PAT; Bickel H; Thurner P; Breitenseher J; Lazar M; Pones M; Peck-Radosavljevic M; Hucke F; Ba-Ssalamah A
    Acad Radiol; 2017 Dec; 24(12):1491-1500. PubMed ID: 28756085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined hepatocellular-cholangiocarcinoma: Gadoxetic acid-enhanced MRI findings correlated with pathologic features and prognosis.
    Park SH; Lee SS; Yu E; Kang HJ; Park Y; Kim SY; Lee SJ; Shin YM; Lee MG
    J Magn Reson Imaging; 2017 Jul; 46(1):267-280. PubMed ID: 27875000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.
    Kim R; Lee JM; Shin CI; Lee ES; Yoon JH; Joo I; Kim SH; Hwang I; Han JK; Choi BI
    Eur Radiol; 2016 Jun; 26(6):1808-17. PubMed ID: 26373763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
    Lee HS; Kim MJ; An C
    Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.